Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The proposed 12-month programme will enable genotyping of blood groups by NHS BT in current patients (up to 17,800 patients) with either sickle cell or thalassemia.
Additional information:
Direct Award justified under Reg 32 as lack of competition due to technical reasons. NHSBT are the only organisation capable of delivering the scope of servcies
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| NHS Blood and Transplant (NHSBT) | - | £854,000 | - |